Valuation: Qiagen NV

Market Cap 8.15B 7.15B 6.59B 6.17B 11.56B 769B 11.8B 79.17B 30.63B 380B 30.6B 29.93B 1,318B P/E 2026 *
18.8x
P/E 2027 * 18x
Enterprise Value 8.71B 7.64B 7.04B 6.59B 12.36B 822B 12.61B 84.6B 32.74B 406B 32.7B 31.99B 1,408B EV / Sales 2026 *
4.04x
EV / Sales 2027 * 3.71x
Free-Float
99.27%
Yield 2026 *
-
Yield 2027 * 0.48%
Manager TitleAgeSince
Chief Executive Officer 61 2019-10-06
Director of Finance/CFO 58 2003-12-31
Chief Operating Officer - 2022-03-31
Director TitleAgeSince
Director/Board Member 77 2011-05-31
Director/Board Member 60 2021-01-07
Director/Board Member 72 2022-06-22
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-4.05% - - 8.05B
-0.48%+8.75%-5.51%+0.91% 46.36B
+2.19%+11.71%+374.04%+613.48% 37.88B
+2.53%+13.93%+20.43%-10.71% 31.12B
+1.65%+3.61%+4.78%+56.12% 30.61B
-4.16%-4.44%+8.53%+16.06% 24.69B
-0.32%+12.96% - - 16.25B
+1.37%+14.53%+69.40%+135.94% 14.85B
+1.00%+9.67%+14.90%+21.88% 13.58B
+3.63%+9.53%+102.95%+104.79% 12.95B
Average +0.51%+7.85%+73.69%+117.31% 25.36B
Weighted average by Cap. +0.61%+7.66%+82.40%+135.51%

Financials

2026 *2027 *
Net sales 2.16B 1.89B 1.74B 1.63B 3.06B 203B 3.12B 20.94B 8.1B 100B 8.09B 7.92B 348B 2.27B 1.99B 1.84B 1.72B 3.22B 214B 3.29B 22.06B 8.54B 106B 8.53B 8.34B 367B
Net income 414M 363M 335M 313M 587M 39.05B 600M 4.02B 1.56B 19.3B 1.55B 1.52B 66.93B 472M 414M 381M 357M 669M 44.49B 683M 4.58B 1.77B 21.99B 1.77B 1.73B 76.24B
Net Debt 559M 490M 452M 423M 793M 52.75B 810M 5.43B 2.1B 26.07B 2.1B 2.05B 90.41B 271M 238M 219M 205M 385M 25.6B 393M 2.64B 1.02B 12.65B 1.02B 997M 43.88B
Logo Qiagen NV
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-